Edwards Lifesciences (EW) Net Income towards Common Stockholders (2009 - 2025)

Edwards Lifesciences has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $27.0 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 31.3% year-over-year to $27.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.6 million (down 99.25% YoY), and the FY2025 full-year result was $13.4 million, down 99.52% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at $27.0 million, up from -$2.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.7 billion in Q3 2024, with the low at -$7.2 million in Q1 2025.
• Average Net Income towards Common Stockholders over 5 years is $314.6 million, with a median of $194.7 million recorded in 2021.
• Year-over-year, Net Income towards Common Stockholders soared 5447.75% in 2024 and sank 540.0% in 2025.
• Tracing EW's Net Income towards Common Stockholders over 5 years: stood at $335.3 million in 2021, then climbed by 18.82% to $398.4 million in 2022, then slumped by 90.81% to $36.6 million in 2023, then gained by 7.38% to $39.3 million in 2024, then tumbled by 31.3% to $27.0 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at $27.0 million (Q4 2025), -$2.0 million (Q3 2025), and -$4.4 million (Q2 2025), per Business Quant data.

Peer Comparison